Hydrogen(H2) treatment for acute erythymatous skin diseases. A report of 4 patients with safety data and a non-controlled feasibility study with H2 concentration measurement on two volunteers

Table 1 Duration of H2 treatment and lab studies of 4 patients

	chemistry					hematology
	GOT	GPT	γ-GPT	T-BIL	CRP	WBC	RBCx10⁴	Plateletx10⁴
Case 1 : 6 days
At the beginning	23	58	96	0.7	1.51	7800	462	32.2
4 days after	16	27	66	0.4	1.89	7800	430	36.8
9 days after (3 days after resumption)	20	22	63			10600	431	52.8
22 days after, (16 days After resumption)	17	12	45		0.19	8000	440	51.6
	chemistry					hematology
	GOT	GPT	γ-GPT	T-BIL	CRP	WBC	RBCx10 ⁴	Plateletx10 ⁴
Case 2:19 days
At the beginning	33	58	253	0.6	8.27	10200	367	29.1
7 days after	20	57	244		8.71	18800	297	20.1
10 days after	27	59	233		9.35	37000	348	3.8
2 weeks after	29	46	210	1.9	6.53	11900	288	1.9
18 days after	19	35	152	1.6	5.81	11200	258	4.6
3 weeks after	15	22	79		8.64	17700	310	24.2
	chemistry					hematology
	GOT	GPT	γ-GPT	T-BIL	CRP	WBC	RBCx10 ⁴	Plateletx10 ⁴
Case 3 : 2hrs
At the beginning	22	25	28			4500	432	13.6
45 days after (45 days after completion)	19	20	25	0.4	0.24	4500	439	15.5
	chemistry					hematology
	GOT	GPT	γ-GPT	T-BIL	CRP	WBC	RBC (万)	Plateletx10 ⁴
Case 4 : 3 days
At the begining	25	35	342		1.31	18000	396	30.6
2 days after	34	36	286		0.65	21900	381	26
5 days after (2 days after completion)	60	117	300		1.91	13200	409	11.7

Administration of H2 did not change physiological parameters and did not cause significant deterioration of the blood chemistry such as for liver and kidney function, although some of these patients already had severe abnormalities before the H2 treatment such as thrombocytopenia of case 2.

ISSN: 2045-9912